Jaffray David A, Gospodarowicz Mary K
More than 14 million new cases of cancer are diagnosed globally each year; radiation therapy (RT) has the potential to improve the rates of cure of 3.5 million people and provide palliative relief for an additional 3.5 million people. These conservative estimates are based on the fact that approximately 50 percent of all cancer patients can benefit from RT in the management of their disease (Barton, Frommer, and Shafiq 2006; Barton and others 2014; Tyldesley and others 2011); of these, approximately half present early enough to pursue curative intent. Soon after Roentgen’s discovery of X-rays in 1895, ionizing radiation was applied to the treatment of cancer, with remarkable results. Carefully controlled doses of ionizing radiation induce damage to the DNA in cells, with preferential effects on cancer cells compared with normal tissues, providing treatment benefits in most types of cancer and saving lives. RT is now recognized as an essential element of an effective cancer care program throughout the world, regardless of countries’ economic status. RT is used to cure cancers that are localized; it also can provide local control—complete response with no recurrence in the treated area—or symptom relief in cancers that are locally advanced or disseminated (Gunderson and Tepper 2012). It is frequently used in combination with surgery, either preoperatively or postoperatively, as well as in combination with systemic chemotherapy before, during, or subsequent to the course of RT (Barton and others 2014). Because radiation affects normal tissues and tumors, achieving an acceptable therapeutic ratio—defined as the probability of tumor control versus the probability of unacceptable toxicity—requires that the radiation dose be delivered within very tightly controlled tolerances with less than 5 percent deviation. This controlled production and precise application of radiation requires specialized equipment that is maintained and operated by a team of trained personnel. The team includes, at a minimum, radiation oncologists to prescribe the appropriate dose, medical physicists to ensure accurate dose delivery, and radiation technologists to operate the equipment and guide patients through the radiation process. Radiation oncologists work within multidisciplinary teams with medical and surgical oncologists to coordinate a multidisciplinary approach to the management of cancer. A comprehensive cancer center provides the full scope of RT services, ranging from externally applied beams of X-rays to the placement of radiation-emitting sources within tumors (see chapter 11 in this volume [Gospodarowicz and others 2015]). RT is one of the more cost-effective cancer treatment modalities, despite the need for substantial capital investment in the facilities and equipment. Concerns about the initial investment, however, have resulted in severely limited access in most low- and middle-income countries (LMICs). Increasing the supply of RT services is critical to expanding effective cancer treatment in these settings and improving equity in access (Abdel-Wahab and others 2013; Fisher and others 2014; Goss and others 2013; Jaffray and Gospodarowicz 2014; Rodin and others 2014; Rosenblatt and others 2013).
全球每年有超过1400万新增癌症病例被诊断出来;放射治疗(RT)有潜力提高350万人的治愈率,并为另外350万人提供姑息治疗。这些保守估计是基于这样一个事实,即所有癌症患者中约有50%可以从放射治疗中受益(Barton、Frommer和Shafiq,2006年;Barton等人,2014年;Tyldesley等人,2011年);其中,大约一半患者就诊时病情足够早,可以进行根治性治疗。1895年伦琴发现X射线后不久,电离辐射就被应用于癌症治疗,并取得了显著效果。精心控制剂量的电离辐射会对细胞中的DNA造成损伤,与正常组织相比,对癌细胞有优先作用,对大多数类型的癌症都有治疗效果并挽救生命。如今,无论国家经济状况如何,放射治疗在全世界都被视为有效癌症护理计划的重要组成部分。放射治疗用于治愈局限性癌症;它还可以提供局部控制——治疗区域完全缓解且无复发——或缓解局部晚期或转移性癌症的症状(Gunderson和Tepper,2012年)。它经常与手术联合使用,无论是术前还是术后,也与全身化疗联合使用,在放疗过程之前、期间或之后(Barton等人,2014年)。由于辐射会影响正常组织和肿瘤,要实现可接受的治疗比——定义为肿瘤控制概率与不可接受毒性概率之比——就要求辐射剂量在非常严格控制的容差范围内输送,偏差小于5%。这种对辐射的受控产生和精确应用需要专门的设备,由一组训练有素的人员进行维护和操作。该团队至少包括规定适当剂量的放射肿瘤学家、确保准确剂量输送的医学物理学家,以及操作设备并指导患者完成放疗过程的放射技师。放射肿瘤学家与医学肿瘤学家和外科肿瘤学家在多学科团队中合作,以协调癌症管理的多学科方法。一个综合癌症中心提供全方位的放射治疗服务,从外部施加的X射线束到在肿瘤内放置辐射源(见本卷第11章[Gospodarowicz等人,2015年])。尽管需要在设施和设备上进行大量资本投资,但放射治疗是成本效益较高的癌症治疗方式之一。然而,由于对初始投资的担忧,大多数低收入和中等收入国家(LMICs)获得放射治疗的机会严重受限。增加放射治疗服务的供应对于在这些地区扩大有效的癌症治疗和改善获得治疗的公平性至关重要(Abdel-Wahab等人,2013年;Fisher等人,2014年;Goss等人,2013年;Jaffray和Gospodarowicz,2014年;Rodin等人,2014年;Rosenblatt等人,2013年)。